Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q2 FY2025 Earnings Presentation
21 slides from Little Green Pharma's earnings presentation, February 2025
Slide 1: December 2024 Quarterly & Appendix 4C Investor Presentation
December 2024 Quarterly & Appendix 4C ASX:LGP Investor presentation FEBRUARY 2025 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
2 Disclaimer Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, activities current as at the
Slide 3: Little Green Pharma
Little Green Pharma 30t 5 BRANDS 31 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 94 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 4: Strong EU & UK market growth
MARKET UPDATE Strong EU & UK market growth Germany 2024 cannabis reform continues to generate significant market growth, with Pillar 2 reform – being pilot projects in 11 German cities to test commercial supply chains – expected to catalyse further demand Pillar 1 reform demand helped drive ~40,000
Slide 5: Strong EU & UK market growth (cont.)
MARKET UPDATE Strong EU & UK market growth (cont.) United Kingdom UK market growing rapidly driven by patient demand and expansion of private clinic networks • Market tripled in size between end 2022 and September 2023 with UK patients consuming 144% more per person than German patients1 • UK market
Slide 6: Strong EU & UK market growth (cont.)
MARKET UPDATE Strong EU & UK market growth (cont.) France Post-trial transition phase extended to 30 June 2025 Current French political environment not expected to materially change proposed market authorisation pathway, Company continuing to prepare product registration applications LGP currently t
Slide 7: New 2tpa grow room
DENMARK UPDATE New 2tpa grow room LGP Denmark expanded into further 2tpa grow room to meet growing European, Australian and UK demand LGP’s Danish facility the largest medicinal cannabis facility in Europe and well positioned to capture German, UK and other European growth Danish government has agre
Slide 8: Market opportunity
MARKET OPPORTUNITY Market opportunity LGP’s global markets KEY Production facility and supplied market Supplied market Supply arrangements LGP holds a 6.5% stake in local producer LGP MARKETS 8
Slide 9: Revenue and cash receipts
REVENUE & CASH RECEIPTS Revenue and cash receipts Revenue vs cash receipts ($000’s) Step change in cash 12,000 receipts with consecutive 10,754 11,000 10,043 quarters above $10.0 million 10,000 9,000 10,138 9,545 Revenue of $9.5 million 8,000 (unaudited) up 75% on prior 7,000 5,295 corresponding qua
Slide 10: Revenue by product category
REVENUE BY PRODUCT CATEGORY Revenue by product category ($000’s) 12,000 Revenue by 10,000 product category 8,000 6,000 Flower sales down 5% predominately 4,000 driven by: 2,000 • demand outstripping supply for 0 CherryCo Smalls FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 • regulatory delays affecting Flower
Slide 11: Revenue by segment
REVENUE BY SEGMENT Revenue by segment ($000’s) 12,000 Revenue by 10,000 segment 8,000 6,000 European sales up 20% predominately driven by: 4,000 • 20% growth in both flower and oil 2,000 sales despite regulatory delays - suspending Australian flower FY24Q4 FY25Q1 FY25Q2 FY25Q3 FY25Q4 shipments into
Slide 12: Revenue by brand
REVENUE BY BRAND Revenue by Revenue by brand ($000’s) brand 12,000 New Craft brand Lush Labs launched late December to initial positive reviews 10,000 CherryCo sales down 25% on prior quarter driven by demand outstripping supply, in part due to redirection of crops to higher priced European markets
Slide 13: Net cashflows from operations
NET CASHFLOWS FROM OPERATIONS Net cashflows Net operating cash outflows of $0.4 million due to working capital and inventory requirements to meet increased demand from operations combined with record December sales for which receipts will be collected in the following months Cashflow from operating
Slide 14: EV, NTA, cash, debt and revenue
EV, NTA, CASH, DEBT AND REVENUE EV, NTA, cash, EV, NTA, cash, debt & annualised revenue ($000’s) debt and revenue 100,000 100,000 Company’s net tangible 80,000 80,000 assets continue to be significantly above enterprise value 60,000 60,000 Minimal long-term debt of 40,000 40,000 $3.2 million Cash in
Slide 15: New brands & products
BRAND & PRODUCT UPDATE New brands & products Company launched: • five new high-THC flower products under Lush Labs and LGP brands (THC24, THC26 and THC28 Indica and Sativa) in late December 2024 • three new oils under CherryCo and LGP brands (CBD100, THC30, THC25:CBD25) • one new live resin vaporisa
Slide 16: New craft flower brand
BRAND & PRODUCT UPDATE New craft flower brand In December 2024 LGP released first two SKUs of new Lush Labs craft flower brand in exclusive partnership with JR Strains to positive early prescriber and patient feedback With Lush Labs, LGP completes first phase of House of Brands strategy with SKUs ac
Slide 17: Health House acquisition
HEALTH HOUSE Health House acquisition Post period end, LGP completed the acquisition of HHI (Australia) Pty Ltd, the owner of the Health House medicinal cannabis distribution business LGP considers this transaction to be an exceptional value acquisition and important step in the Company’s long-term
Slide 18: RESET update
RESET UPDATE update Clinical trial has finished treatment phase with patients receiving follow up analyses over next 12 months Lots of positive patient feedback with no significant adverse events recorded, results to be analysed after follow-up phase and clinical outcomes published separately 18
Slide 19: Corporate overview
CORPORATE OVERVIEW Corporate overview Capital structure Shareholder structure Current share price1 $0.12 Shares outstanding1 ~302 million Options and performance rights on Issue2 ~24.7 million 22% 29% Market capitalisation (undiluted) ~$36.2 million Cash reserves (31 December 2024) ~$3.7 million 9%
Slide 20: Delivering on strategy
THE NEXT 6 MONTHS Delivering on strategy Continued growth into German and UK markets with $6 million in POs Integration of Health House including taking synergies and cost savings Growing CherryCo and Germany & UK flower supply through new 2tpa room Identifying opportunities in continued shakeout of
Slide 21: Q&A
Q&A Paul Long, CEO A world of difference investor.littlegreenpharma.com
Little Green Pharma — Q2 FY2025 Earnings Presentation on 6ix